Trial · NCT01914757
Results by group140
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 140
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uL | Benralizumab 30 mg q.4 Weeks | 0.6 | 95% Confidence Interval 0.48 to 0.74 | Events/year | |
| Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uL | Benralizumab 30 mg q.8 Weeks | 0.66 | 95% Confidence Interval 0.54 to 0.82 | Events/year | |
| Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uL | Placebo | 0.93 | 95% Confidence Interval 0.77 to 1.12 | Events/year | |
| Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils <300/uL | Benralizumab 30 mg q.4 Weeks | 0.78 | 95% Confidence Interval 0.59 to 1.02 | Events/year | |
| Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils <300/uL | Benralizumab 30 mg q.8 Weeks | 0.73 | 95% Confidence Interval 0.55 to 0.95 | Events/year | |
| Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils <300/uL | Placebo | 1.21 | 95% Confidence Interval 0.96 to 1.52 | Events/year | |
| Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils >=300/uL | Benralizumab 30 mg q.4 Weeks | 0.34 | Standard Deviation 0.469 | Liter | |
| Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils >=300/uL | Benralizumab 30 mg q.8 Weeks | 0.332 | Standard Deviation 0.518 | Liter | |
| Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils >=300/uL | Placebo | 0.206 | Standard Deviation 0.471 | Liter | |
| Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils <300/uL | Benralizumab 30 mg q.4 Weeks | 0.221 | Standard Deviation 0.441 | Liter | |
| Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils <300/uL | Benralizumab 30 mg q.8 Weeks | 0.164 | Standard Deviation 0.358 | Liter | |
| Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils <300/uL | Placebo | 0.135 | Standard Deviation 0.437 | Liter | |
| Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils >=300/uL | Benralizumab 30 mg q.4 Weeks | -1.33 | Standard Deviation 1.23 | Scores on a scale | |
| Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils >=300/uL | Benralizumab 30 mg q.8 Weeks | -1.4 | Standard Deviation 1.17 | Scores on a scale | |
| Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils >=300/uL | Placebo | -1.2 | Standard Deviation 1.19 | Scores on a scale | |
| Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils <300/uL | Benralizumab 30 mg q.4 Weeks | -1.05 | Standard Deviation 1.14 | Scores on a scale | |
| Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils <300/uL | Benralizumab 30 mg q.8 Weeks | -0.95 | Standard Deviation 1.13 | Scores on a scale | |
| Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils <300/uL | Placebo | -0.88 | Standard Deviation 1.12 | Scores on a scale | |
| Change in Asthma Rescue Medication Use | Benralizumab 30 mg q.4 Weeks | -2.0 | Standard Deviation 3.64 | Puffs per day | |
| Change in Asthma Rescue Medication Use | Benralizumab 30 mg q.8 Weeks | -2.92 | Standard Deviation 3.60 | Puffs per day |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01914757/results